Compare Innovative Industrial Properties Inc (IIPR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Neurocrine Biosciences Inc — how do they compare? Innovative Industrial Properties Inc trades at $51.85 (market cap $1.43B), while Neurocrine Biosciences Inc trades at $142.6 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 10× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 14.64% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Innovative Industrial Properties Inc for 86 Days and Neurocrine Biosciences Inc for 23 Days on average.
| IIPR | NBIX | |
|---|---|---|
Market Cap | $1.43B | $14.36B |
Volume | 394,222 | 1,237,180 |
Sector | Real Estate | Health |
52-Week High | $64.67 | $185.50 |
52-Week Low | $44.58 | $123.10 |
Typical Hold Time | 86 Days | 23 Days |
Enterprise Value | $1.96B | $14.37B |
Dividend Yield | 14.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $51.87, up 1.25% on the day, with a bearish technical signal from moving averages. The stock shows mixed earnings, beating in Q2 but missing in Q1, with revenue declining to $266 million in 2025. Valuation ratios appear attractive with a P/E of 11.75 and P/B of 0.83, while the company maintains a high net income margin of 52.27%. Recent news highlights a $245 million mezzanine loan commitment and a declared $1.90 dividend.
The outlook is cautious due to declining revenue and negative net cash flow in 2025, offset by strong profitability and a discounted valuation. Risks include tenant defaults and dividend sustainability concerns, but analyst consensus suggests upside with a $84.67 price target. The stock presents a high-yield opportunity with significant re-rating potential if operational challenges are managed.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
